brain stem controller concemed with automatic (or involuntary) breathing and (2) a secondary cerebral controller which superimposes behavioural (or voluntary) influences on ventilation. The brain stem controller receives and integrates various inputs and then sends impulses through motor neurons to the effectors or ventilatory muscles. The cerebral controller directs the same cffcctors but its inputs are complex and poorly understood.
The inputs to the brain stem controller provide the drive for automatic breathing. Since this controller is fundamentally concerned with maintaining oxygenation and acid/base homeostasis, its principle inputs arise from chemoreceptors which sense variables of oxygen and acid/base balance. Two sets of chemoreceptors perfom~ this function: one in the medulla sensitive to brain PCO2-[H +] activity; the other in the carolid bodies reactive to the PO: and PCOz-[H-1 of arterial blood. The effective input of each appears at thresholds of PO 2 and/or PCOT[H +] and then increases in relation to reductions of P02 and/or increments of PCO2-[H+I. A second type of input to the automatic controller arises from the nonspecific neural activity or "traffic" in the brain stem reticular formation. Although not as well characterized, this input likely mediates the effects of wakefulness and noxious stimulation on breathing} The wakefulnessrelated input adds only slightly 1o normal resting chemoreceptor drive, but becomes critically important when the chemoreceptor input is severely impaired. If, for example, chemoreceptor drive is abolished -as with a low PC02 and high PO2 -an input related to wakefulness can take over and maintain breathing at about two-thirds normal values. 3 Other types of input originate with the mechanoreceptors of the lungs and chest wall and the baroreceptors of the cardiovascular system. These are not pertinent to this presentation.
The effectors of the system are the two groups of muscles that achieve ventilation: (1) the muscles of the K.nilh CONTROL OF BREATHING $5 upper airway (e.g., genioglossus and posterior cricoaryteholds) and (2) the muscles of the chest wall (diaphragm, intercostals and accessories). Each group displays two types of activity: (1) intermittent or phasic and (2) continuous or tonic. 4's The phasic activity generates inspiration. That of the upper airway muscles enlarges the airway with each breath; that of the chcst wall muscles acts to inflate the lungs. The tonic activity performs certain "posturar' functions. That of the genioglossus helps to keep the airway open between breaths 4 and that of the diaphragm helps maintain the end-expiratory lung volume (i.e., FRC) in the supine positionJ
Sedatives/hypnotics/tranquillizers
This varied group of CNS depressants, which includes the barbiturates, phenothiazines and benzodiazepines, has no important effect on resting breathing if given in doses that produce only sedation or light sleep. However, these agents do impair certain mechanisms of breathing control and as a result may affect breathing in vulnerable patient groups. Sedative/hypnotics can reduce the venti[atory responses to chemoreceptor stimuli, i.e., added CO2 6 and/or hypoxaemia. 7 In patients who have chronic ventilatory failure (e.g., with COPD) and thus reduced responses to chemoreceptor stimuli related to disease, the added depressive effect of these drugs can be sufficient to worsen ventilatory failure and precipitate a respiratory crisis s -especially in association with loss of wakefulness or sleep. 9 Sedative/hypnotics also suppress the normal tone of the e/lector muscles of the upper airway, m In patients with the obstructive sleep apnoea syndrome and an anatomical predisposition to upper airway obstruction, this relaxing effect is believed to be responsible for an increase in the number and severity of apnoeas during sleep, t l
Narcotic analgesics
All narcotic analgesics (morphine, meperidine, fentanyl, etc.) are potent ventilatory depressants. Equi-analgesic doses of individual agents have quantitatively similar effects. In the usual analgesic doses, they depress breathing primarily by reducing the breathing rate and increase PaCO2 3 or 4 mmHg. These effects increase with dose until, at the point of loss of consciousness or "sleep," periodic breathing or apnoea occurs. Those agents that possess both agonist and antagonist activity (e.g., nalbnphine) display a ceiling of ventilatory depression at moderate doses. However, this is of little therapeutic advantage since their analgesic effect is limited too. t2
Narcotics also alter the mechanisms of breathing control. Accompanying the changes in resting breathing and PaCO2 are dose-related reductions of the responses to chemoreceptor stimuli, both added CO2 and hypoxaemia, 13 Thus, patients who have ventilatory failure and preexisting impaired responses to these stimuli are also more sensitive to narcotic effect s As responses to chemoreceptor stimuli are obtunded by a narcotic, ventilation becomes more dependent upon the input of wakefulness. Thus, loss of wakefulness -as with natural nonREM sleep -appears to potentiate narcotic induced ventilatory depression.14 The magnitude of this effect is modest at an ordinary analgesic dose, t4 but can be dramatic in the presence of a larger dose, in which case loss of wakefulness or sleep may precipitate severe hypopnoea or apnoea.'S Such sleep induced apnoea can be reversed by arousing the patient and prompting him to breathe, i.e., by making use of the wakefulness and/or behavioural control mechanisms.
Any drug or drug combination which abolishes wakefulness has the potential to greatly exaggerate narcotic depression of breathing. For example, a larger dose of narcotic by itself may reduce breathing only modestly. However, the addition of a small dose of sedative or tranquillizer which, with the narcotic, induces sleep can result in marked hypopnoea or apnoea, tS Thus when a narcotic and a tranquillizer are given together, as in neu~:oleptanalgesia, the dose of narcotic should be judicious and limited to that which is necessary to relieve pain (see below). Anaesthetizing doses of volatile anaesthetics also potentiate narcotic-induced ventilatory depression, such that even a relatively small dose of narcotic given during anaesthesia may cause severe hypoventilation or apnoea.
Noxious stimulation or pain increases the brain stem neural activity and effectively antagonizes the depression of ventilation associated with analgesic doses of narcotic. When using a narcotic to treat acute pain, one can virtually always administer it to the point of pain relief without concern for depressed breathing, reg~dless of the absolute dose required. This important point is too often forgotten in clinical practice.
Certain ventilatory effects of narcotic pertain to particular methods of administration. Rapid intravenous administration of a moderate to large dose can induce muscle spasm and rigidity of the chest wall to an extent that severely limits ventilation.16 N2 O potentiates this effect and neuromuscular blockade effectively abolishes it. Epidural or subarachnoid administration of a relatively small dose of water-soluble narcotic (e.g., morphine) occasionally causes profound ventilatory depression which is delayed and apparently due to slow transport of morphine in the spinal CSF to the brain stem. J7 Old age, respiratory disease and/or concomitant parenteral narcotic predispose to this effect. ,7 Chronic pain and/or narcotic tolerance may be protective.
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Inhalafional and intravenous anaesthetics
The modem halogenaled anaesthetics (halothane, isoflurane and enflurane) are also potent venfilatory depressants, but only when given in doses that produce loss of wakefulness and anaesthesia. At such doses, they reduce ventilation and tidal volume, increase breathing frequency and elevate PaCO2 -all in proportion to anaesthetic depth. The magnitude of hypoventilation varies considerably amongst equipotent doses of individual agents. At 1.0 MAC, halothane increases the average PaCO2 value to about 45 mmHg while isoflarane increases it to 50 mmHg and enflurane to over 65 mmHg (making enflurane in oxygen unacceptable for spontaneous breathing). Contrary to popular expectation, depression of ventilation does not increase with anaesthetic durationbut rather decreases, in a kind of "adaptation."18 Surgical stimulation usually counteracts depression somewhat, reducing the PaCO2 about 5 mmHg. t9
Halogenated agents have several important actions on the mechanisnls of breathing control.
First, they obtund responses to all chemoreceptor stimuli, ~9-2~ independent of surgical stimulation_ 22 At anaesthetic doses, the slope of the response to added CO~ is depressed in a dose-related fashion -more or less in parallel with the changes in resting ventilation and PaCO2,19 Thus, patients with pre-existing impaired CO2 responsiveness, such as those with COPD, hypoventilate more during anaesthesia. 2~ This insensitivity to added CO:: during anaesthesia is the rationale for avoiding rebreathing in all spontaneously breathing patients since rebreathing increases the CO2 level much more when the CO2 response slope is reduced.
More severely affected are the reactions to hypoxaemia and to added [H+]a or metabolic acidaemia. Anaesthetic doses of halogenated agents completely abolish these responses such that ventilation is unaffected by either the oxygen tension or the acidity of the blood, 2~ Subanaesthetic doses markedly suppress them. 2~ Accordingly, those patients who depend upon the input of hypoxaemia or acidaemia to sustain ventilation (e.g., the COPD patient who has lost his sensitivily to CO2 or the patient with acute metabolic aeidaemia requiring hyperventilation to defend [H+]) will breathe inadequately during and tollowing anaesthesia. Further, if acute hypoxaemia or metabolic acidaemia develop during or after anaesthesia, neither ventilatory compensation nor signs of respiratory distress appear.
Second, anaesthesia abolishes wakefulness and thereby renders ventilation completely dependent upon chemoreceptor input)* In the case of the halogenated anaesthetics, chemoreceptor input relates ~olely to CO2. 2t Thus any factor during halogenated, hydrocarbon anaesthesia which removes the CO2 stimulus (passive hyperventila fion) or completely suppresses CO2 responsiveness (e. g., sufficient narcotic) abolishes all ventilatory activity and results in apnoea. These factors are made use of in instituting "controlled apnoea" for controlled ventilation.
This dependence on CO2-related input can give rise to a particular hazard during early recovery, from anaesthesia in which controlled ventilation has been employed and conditions for "controlled apnoea" continue to exist, i.e., (1) the PCO2 level remains below its stimulating threshold and/or (2) CQ responsiveness remains markedly impaired. A drowsy but awake patient may breathe adequately in these circumstances (due to the input of wakefulness) but loss of wakefulness can precipitate severe hypopnoea or apnoea. Since wakefulness cannot be assured throughout the recovery period? and since early postanaesthetic levels of halogenated agent continue to render CO2 the only reliable chemoreceptor stimulus,2m continuous breathing during recovery must be considered to be still completely dependent upon CO2. Accordingly, at the end of anaesthesia involving controlled ventilation, both a stimulating level of CO2 and an adequate CO2 response must be provided for the recovery period. The presence of wakefulness and ventilation during wakefulness does not guarantee adequate breathing throughout the recovery period.
Third, the halogenated agents cause a preferential depression of certain functions of the eflector system. In anaesthetic doses, they markedly suppress the activity of upper airway muscles of the tongue, predisposing to airway obstruction. This action is potent and evident at even subanaesthetic doses. 23 They also preferentially depress intercostal muscle activity and the tonic activity of the diaphragm at end-expiration. 24'2~ The selective loss of intercostal activity reduces the thoracic or rib cage contribution to spontaneous ventilation.~4 The relaxation of the diaphragm at end-expiration, together with the loss of intercostal activity, is likely the principal factor responsible for the reduced end-expiratory volume (FRC) during anaesthesia (with either spontaneous or controlled ventilation), s The reduced FRC undoubtedly underlies the microatelectasis, pulmonary shunting and impairment of oxygen uptake associated with anaesthesia. 2s
The importance of these various effects on effcetor muscle activity depends at least in part upon the structural and mechanical characteristics of the ventilatory system. For example, compared to a patient with normal airway anatomy, an obese patient who has excessive fat about the upper airway is more susceptible to airway obstruction from loss of upper airway muscle activity. Similarly, an obese patient with added fat weighing upon the abdomen and chest wall suffers a greater reduction of FRC and a more severe impairment of oxygenation from loss of diaphragm tone.
The intravenous barbiturate anaesthetics (thiopentone methohexitone) have similar effects on breathing and the breathing control system except they do not cause a preferential loss of the response to hypoxaemia. Ketamine and nitrous oxide (N20) are unique in having no effect on resting breathing in typical clinical doses. Including these latter agents in an anaesthetic mixture -and thereby decreasing the dose of other agents -can substantially reduce overall ventilatory depression. Thus, while enflurane 1.0 MAC alone causes an unacceptable degree of ventilatory depression, a 1,0 MAC mixture of enflurane and N20 70 per cent permits adequate spontaneous breathing. 26
Neuromuscular blocking drugs
The ventilatory effects of the neuromuscular blocking agents (suecinylcholine, tnbocurarine, pancuronium, etc.) result solely from their actions on the neuromuscular junctions of effector muscles, Their effect on individual muscle groups varies considerably. Amongst the muscles of the chest wall, the expiratory abdominal muscles and intercostals are the most sensitive, the inspiratory intercostals somewhat less so and the diaphragm least of all. 27~2s At typical clinical doses of paneuronium, expiratory fbrce is abolished but the diaphragm is only slightly impaired. 29 The effector muscles which are the most readily compromised by the neuromuscular blocking agents are those of the upper airway. With increasing doses of tubocurarine, the earliest clinically detectable ventilatory effect is obstruction of the upper ai~vay.3~ Upper airway resistance increases 3! and inspiratory flow decreases 2s before there are important reductions of vital capacity or chest wall muscle strength. This is sometimes due to an inability to clear (i.e., swallow) secretions but more often due to soft tissue collapse no doubt the result of weakened muscles of the pharynx, tongue and/or jaw. Thus, in managing neuromuscular blockade and its recovery, one must be attentive not only to the ventilatory muscles of the chest wall but in particular to those which maintain the airway.
Conclusion
Analgesic, anaesthetic and neuromuscular blocking drugs interfere with the ventilatory system in several discrete and specific ways. Awareness of their various actions improves clinical rationale for the safe management of ventilation in the peri-anaesthetic period.
